Highest-materiality recent filing
OPKO Health issues $125M additional senior secured notes due 2044
Issued $125M additional senior secured notes under amended Note Purchase Agreement dated Aug 13, 2026.
OPKO Health Q2 2026 net loss narrows to $8.4M; provides FY 2026 revenue guidance $560-585M
Consolidated revenue $163.5M vs $156.8M YoY; operating loss improved to $7.0M from $60.0M.
OPKO Health Q1 revenue falls to $124.2M, net loss narrows; pipeline advances
Consolidated revenue $124.2M vs $149.9M YoY; net loss $54.8M ($0.07/sh) from $67.6M ($0.10/sh).
OPKO Health Q4 revenue $148.5M, net loss $31.3M; Regeneron deal >$1B
Q4 revenue $148.5M (down 19% YoY); net loss $31.3M ($0.04/share) vs $14.0M income in Q4 2024.
Q3 consolidated revenues $151.7M, down 12.6% YoY; operating income $48.1M vs $14.2M; diluted EPS $0.03 flat.
OPKO completes sale of BioReference oncology assets to Labcorp for $192.5M cash plus earnout
Transaction closed Sept 15, 2025; Labcorp paid $192.5M at closing, with up to $32.5M earnout.
OPKO Health Q2 revenue $156.8M down 14% YoY; net loss includes $91.7M convertible note charge
Consolidated revenue $156.8M vs $182.2M in Q2 2024; net loss $148.4M ($0.19/share) vs $10.3M loss ($0.01) prior year, including $91.7M non-recurring convertible note expense.
OPKO Health grants stock options and bonuses to CEO Frost and other executives
Compensation Committee granted stock options for 500,000 shares to CEO Phillip Frost, each at $1.31 exercise price.
Revenue $149.9M vs $173.7M YoY; net loss $0.10 per share vs $0.12 per share.
OPKO Health exchanges $159.2M convertible notes for 121.4M shares and $63.5M cash
Exchanged $152.5M (Mar 27) plus $6.75M (Mar 28) of 3.75% Convertible Senior Notes due 2029.
OPKO Health to exchange $152.5M convertible notes for 116.7M shares and ~$60.1M cash
Exchange of $152,471,000 principal of 3.75% Convertible Senior Notes due 2029 for 116,706,310 common shares and ~$60.1M cash, including accrued interest.
OPKO Health to sell oncology testing assets to Labcorp for up to $225M
Purchase price: $192.5M at closing plus up to $32.5M in earnout based on performance.
OPKO Health reports Q4 net income of $14M, revenue $183.6M; BARDA/Merck milestones boost pharma
Consolidated Q4 revenue $183.6M vs $181.9M; net income $14.0M ($0.01 diluted EPS) vs net loss of $66.5M in Q4 2023.
OPKO reports Q3 net income $24.9M; sells BioReference assets for $237.5M, authorizes $100M buyback
Q3 revenue $173.6M vs $178.6M YoY; net income $24.9M ($0.03/diluted) vs net loss $84.5M ($0.11) in 2023.
OPKO Health closes $237.5M sale of BioReference clinical diagnostics assets to Labcorp
Labcorp acquired select BioReference diagnostics assets outside NY/NJ for $237.5M cash.
OPKO reports Q2 net loss $10.3M; enters $250M note deal, plans $100M buyback
Q2 total revenues $182.2M (down from $265.4M YoY); operating loss $61.7M vs income $7.0M; net loss $0.01/share.
Notes bear interest at 3-month SOFR + 7.5% (floor 4%); interest-only for first 4 years.
OPKO Health to sell BioReference assets to Labcorp for $237.5M; Q1 net loss $81.8M
Agreed to sell select BioReference Health assets to Labcorp for $237.5M; assets generate ~$100M annual revenue; closing expected H2 2024.
OPKO Health sells BioReference clinical diagnostics business to LabCorp for ~$237.5M
Asset Purchase Agreement with LabCorp for $237.5M cash, excluding oncology/urology and NY/NJ operations.
OPKO Health Q4 revenue $181.9M; net loss narrows to $0.09/sh; $230M convertible notes issued
Consolidated revenue $181.9M vs $185.4M in prior-year quarter; net loss $65.5M ($0.09/sh) vs $85.2M ($0.11/sh).
OPKO Health closes $301M convertible note offering, repurchases stock and existing debt
Issued $230M of 144A Notes and $71.1M of Affiliate Notes (3.75% due 2029); net proceeds $221.4M from 144A.
$200M principal, 3.75% rate, matures Jan 15, 2029; initial conversion price ~$1.15 (26.8% premium).
OPKO Health launches $200M convertible notes offering due 2029; plans stock and note buybacks
Private offering of $200M aggregate principal of Convertible Senior Notes due 2029, plus $30M greenshoe.
OPKO Q3 net loss $84.5M; revenues flat; BARDA awards $59M contract for ModeX
Net loss $84.5M ($0.11/sh) vs $86.1M; operating loss improved to $64.4M from $87.8M YoY.
ModeX (OPKO subsidiary) received initial $59M from BARDA for MSTAR multispecific antibody Phase 1 trial against SARS-CoV-2.
OPKO reports Q2 2023 net loss of $19.6M; receives $90M milestone from Pfizer for NGENLA approval
Consolidated revenue $265.4M, down from $309.9M YoY; operating income $7.0M vs loss of $10.7M.
OPKO Health Q1 revenue down 28% YoY to $237.6M; net loss narrows to $0.02/share
Pharmaceuticals revenue up to $40.4M (vs $36.6M) driven by Rayaldee and IP transfers including $50M Merck upfront.
OPKO subsidiary ModeX licenses EBV vaccine to Merck for $50M upfront, up to $872.5M milestones
ModeX grants Merck exclusive worldwide license for MDX-2201, a preclinical nanoparticle vaccine targeting EBV.
OPKO Health Q4 2022 revenue drops to $185.4M; net loss $85.2M
Consolidated revenue $185.4M vs $401.3M YoY; net loss $85.2M ($0.11/share) includes $49.1M non-cash charge on GeneDx investment.
OPKO extends $55M convertible notes maturity to Jan 2025, lowers conversion price to $1.66
Original $55M 5% convertible notes due Feb 2023 amended to extend maturity to Jan 31, 2025.
OPKO Health reports Q3 net loss of $86.1M as COVID testing revenue collapses
Consolidated revenue $179.7M, down 53% YoY from $385.8M, driven by lower COVID-19 testing.
OPKO Health Q2 net loss of $101.7M on $309.9M revenue; NGENLA launch, ModeX acquisition
Acquired ModeX for $300M in stock; Dr. Zerhouni appointed President/Vice Chairman, Dr. Nabel Chief Innovation Officer.
OPKO Health settles DOJ investigation for $10M; admits improper physician payments
Settlement resolves False Claims Act allegations; total payment $10M plus 1.5% annual interest from Sep 2021.
OPKO Health acquires ModeX Therapeutics for $300M in stock; appoints Dr. Zerhouni as President
Merger consideration of $300M paid via 89,907,310 shares of OPKO common stock.
OPKO Health Q1 net loss $55.4M; completes ModeX acquisition for $300M and GeneDx sale
Q1 consolidated revenue $329.2M (down from $545.2M); net loss $55.4M ($0.08) vs net income $31.1M ($0.05) prior year.
On February 9, 2024, Alexis Borisy, a member of the Board of Directors (the “ Board ”) of OPKO Health, Inc. (the “ Company ”), and a member of Compensation Committee of the Board, informed the Board that he does not intend to stand for reelection at the Company’s 2024 Annual Meeting of Stockholders.
On August 16, 2022, Dr. Jon R. Cohen, retired from his positions as Senior Vice President of OPKO Health, Inc., a Delaware corporation (the “ Company ”), and Executive Chairman and Chief Executive Officer of BioReference Health, LLC
On the Closing Date, in connection with the transactions contemplated by the Merger Agreement, the Board expanded its size from 10 to 13 directors and appointed Elias Zerhouni, M.D. as the Company’s President and Vice Chairman of the Board, Gary Nabel, M.D., Ph.D., as the Company’s Chief Innovation Officer and a director, and Alexis Borisy as a director.
On the Closing Date, in connection with the transactions contemplated by the Merger Agreement, the Board expanded its size from 10 to 13 directors and appointed Elias Zerhouni, M.D. as the Company’s President and Vice Chairman of the Board, Gary Nabel, M.D., Ph.D., as the Company’s Chief Innovation Officer and a director, and Alexis Borisy as a director.
On the Closing Date, in connection with the transactions contemplated by the Merger Agreement, the Board expanded its size from 10 to 13 directors and appointed Elias Zerhouni, M.D. as the Company’s President and Vice Chairman of the Board, Gary Nabel, M.D., Ph.D., as the Company’s Chief Innovation Officer and a director, and Alexis Borisy as a director.
On January 21, 2022, Dr. Robert Fishel notified OPKO Health, Inc. (the “ Company ”), that he was retiring from service on the Company’s Board of Directors (the “ Board ”), effective January 21, 2022.
Max materiality 0.85 · Median 0.70 · Most common event earnings